FDA Approved: TYRUKO — Supplemental Application (Sandoz Inc)

View source ↗

Summary

FDA approved a supplemental application for TYRUKO (natalizumab-sztn) from Sandoz Inc, updating the regulatory file for this biosimilar under the existing natal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Multiple Sclerosis

Drugs mentioned

• TYRUKO (natalizumab-sztn)

Snippet

SUPPL AP for TYRUKO (NATALIZUMAB-SZTN)